Biolidics Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Biolidics non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Hua Zhu	Executive Chairman	less than a year	Nessun dato	29.9% SGD 5.1m
Lu Chen	President & Executive Director	less than a year	Nessun dato	Nessun dato
Chwee Lim	Founder and Advisor	no data	Nessun dato	0.43% SGD 73.3k
Tan Jin	Co-Founder and Technical Advisor	no data	Nessun dato	Nessun dato
Lau Wei Kian	Financial Controller	less than a year	Nessun dato	Nessun dato
Ali Bhagat	Technical Director	no data	Nessun dato	Nessun dato
Hafiza Alwi Nor	Company Secretary	2.3yrs	Nessun dato	Nessun dato

0.6yrs

Durata media

Gestione esperta: Il team dirigenziale di 8YY non è considerato esperto (durata media 0.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Hua Zhu	Executive Chairman	less than a year	Nessun dato	29.9% SGD 5.1m
Lu Chen	President & Executive Director	less than a year	Nessun dato	Nessun dato
Ian David Brown	Non-Executive Independent Director	3.4yrs	Nessun dato	Nessun dato
Li-Ling Ch'ng	Lead Independent Director	1.7yrs	Nessun dato	Nessun dato
Yoke Pheng Liew	Non-Executive Independent Director	less than a year	Nessun dato	Nessun dato

1.0yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 8YY non è considerato esperto (durata media del mandato 1 anni), il che suggerisce un nuovo consiglio.

Biolidics Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Lead Independent Director and Member of the AC and RR

Biolidics Limited Announces the Resignation of Siu Yeung Sau as Financial Controller

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 3Q 2023)

Biolidics Limited (Catalist:8YY) completed the acquisition of Shenzhen Xiaozhao Network Technology Co., Ltd from Dreamsgame Inc.

New major risk - Shareholder dilution

Second quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 2Q 2023)

Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Lead Independent Director and Member of the AC and RR

Biolidics Limited Announces the Resignation of Siu Yeung Sau as Financial Controller

First quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 1Q 2023)

New major risk - Revenue size

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director

New minor risk - Insider selling

Full year 2023 earnings released: S$0.004 loss per share (vs S$0.033 loss in FY 2022)

Biolidics Limited has completed a Follow-on Equity Offering in the amount of SGD 1.0043 million.

Biolidics Limited has completed a Follow-on Equity Offering in the amount of SGD 1.0043 million.

High number of new and inexperienced directors

Biolidics Limited Appoints Zhu Hua as A Non-Executive Non-Independent Director

Biolidics Limited Announces Board Changes

Biolidics Limited has filed a Follow-on Equity Offering in the amount of SGD 1.17215 million.

Third quarter 2023 earnings released: S$0.001 loss per share (vs S$0.003 loss in 3Q 2022)

New major risk - Share price stability

Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Independent Director and Non-Executive Independent Chairman, Chairman of the Ac and Member of the NC and the RC

Second quarter 2023 earnings released: S$0.001 loss per share (vs S$0.004 loss in 2Q 2022)

First quarter 2023 earnings released: S$0.001 loss per share (vs S$0.004 loss in 1Q 2022)

Full year 2022 earnings released: S$0.033 loss per share (vs S$0.023 loss in FY 2021)

Biolidics Limited Provides Group Earnings Guidance for the Financial Year Ended 31 December 2022

High number of new and inexperienced directors

Third quarter 2022 earnings released: S$0.003 loss per share (vs S$0.006 loss in 3Q 2021)

High number of new and inexperienced directors

Biolidics Limited Announces Management Changes

First half 2022 earnings released

Biolidics Limited Announces Company Secretary Changes

Biolidics Limited Ordinary Shares Japan to Be Deleted from OTC Equity

Biolidics Limited Announces Company Secretary Changes, Effective from 24 June 2022

Biolidics Limited Announces Resignation of Leong Man Chun as Chief Scientific Officer

Biolidics Limited Appoints Siu Yeung Sau as Financial Controller

Full year 2021 earnings released: S$0.023 loss per share (vs S$0.018 loss in FY 2020)

Biolidics Limited, Annual General Meeting, Apr 28, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Biolidics Limited Announces Changes to the Composition of the Board of Directors and Board Committees of the Company

High number of new directors

Biolidics Limited Provides Update on Development of the ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit and Receipt of CE Marking

Director Chee Keong Kong sitting on 3 company boards

Chief Operating Officer Qingyin Wang has left the company

Independent Director has left the company

Independent Director has left the company

Full year 2020 earnings released: S$0.018 loss per share (vs S$0.02 loss in FY 2019)

Biolidics Limited Provides Update on ClearEpi SARS-CoV-2 Antigen Rapid Test Kit

New 90-day low: S$0.28

Full year 2020 earnings released

Biolidics Limited Announces Distribution Agreement with Joysbio (Tianjin) Biotechnology Co, Ltd

New 90-day low: S$0.28

New 90-day low - S$0.28

Earnings released

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media